Yohann Loriot is a medical oncologist at the Gustave Roussy Cancer Institute Cancer Campus of the Université Paris-Saclay in the Villejuif commune of Paris, France.

Dr. Loriot’s major research focus involves the study of molecular mechanisms mediating progression to lethal disease in bladder and prostate cancer and use of this information to develop novel strategies and therapies. Dr Loriot is currently member of steering committee of multiple international clinical trials from phase I to phase III leading him to be co-author of collaborative work (published in N Engl J Med, Nature, Lancet Oncology, European Urology, J Clin Oncol). He has been involved in trials leading to several drug approvals (enzalutamide, abiraterone, atezolizumab). He is now developing ancillary studies to better understand the mechanisms of actions and resistance to these new drugs (targeted therapies and checkpoints inhibitors) (MATCH-R study).